🚀 ProPicks AI Hits +34.9% Return!Read Now

EU drugmakers urge June decision on new location for watchdog

Published 23/04/2017, 23:10
© Reuters. FILE PHOTO:  Guido Rasi, executive director the European Medicines Agency (EMA), poses for a portrait at his office in London
SASY
-
PFE
-

FRANKFURT (Reuters) - Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU.

The European Medicines Agency (EMA), employing nearly 900 staff, acts as a one-stop-shop for approving new treatments and monitoring the safety of drugs and veterinary products across the region.

The new location will be decided by the EU's heads of state, whose next meeting as the European Council is scheduled for June 22-23.

"The Council's deliberations on the Agency's future location need to be conducted on the basis of very essential criteria and put for decision as early on as possible, preferably at its meeting in June this year," European pharma lobby group EFPIA said in a statement on Monday signed by 19 top executives at member companies including Pfizer (NYSE:PFE), Novartis, Sanofi (PA:SASY) and Roche.

The industry warned that getting it wrong could impact the region's high level of public health.

"Were a rapid resolution on the future location of the EMA not to materialise, or if the future seat of the European Medicines Agency were to fail in terms of establishing its minimum prerequisites, the quality of its work and the future of the European Medicines Regulatory Network would be placed in jeopardy," the statement said.

EMA's executive director Guido Rasi earlier this month also called for a decision in June and for a carefully planned relocation so as not to disrupt the body's work.

The EMA, the largest EU body in Britain, has been based in London since its birth in 1995 and it moved into new premises in Canary Wharf on a 25-year lease less than three years ago.

No fewer than 21 EU member states have expressed their interest in hosting the EMA, including Italy, Denmark, Sweden, Spain, France, Ireland and Poland.

The new location would have to offer sufficient transport infrastructure and accommodation for EMA staff and its tens of thousands of annual visitors and quality housing, schools and employment opportunities for spouses and family to retain its staff.

© Reuters. FILE PHOTO:  Guido Rasi, executive director the European Medicines Agency (EMA), poses for a portrait at his office in London

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.